Sage Therapeutics to Present at BMO Prescriptions for Success Healthcare Conference
December 07 2017 - 5:02PM
Business Wire
Sage Therapeutics (NASDAQ: SAGE), a clinical-stage
biopharmaceutical company developing novel medicines to treat
life-altering central nervous system (CNS) disorders, today
announced that Sage will participate in a fireside chat
presentation at the BMO Prescriptions for Success Healthcare
Conference on Thursday, December 14, 2017 at 1:30 P.M. ET in New
York.
A live webcast of the presentation can be accessed on the
investor page of Sage's website at investor.sagerx.com. A replay of
the webcast will also be archived for up to 30 days on Sage's
website following the conference.
About Sage Therapeutics
Sage Therapeutics is a clinical-stage biopharmaceutical
company committed to developing novel medicines to transform the
lives of patients with life-altering central nervous system (CNS)
disorders. Sage has a portfolio of novel product candidates
targeting critical CNS receptor systems, GABA and NMDA. Sage's lead
program, a proprietary IV formulation of brexanolone (SAGE-547),
has completed two Phase 3 clinical trials in postpartum depression.
Sage is developing its next generation modulators, including
SAGE-217 and SAGE-718, in various CNS disorders. For more
information, please visit www.sagerx.com.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20171207006259/en/
Investor Contact:Sage TherapeuticsPaul Cox,
617-299-8377paul.cox@sagerx.comorMedia Contact:Suda
Communications LLCMaureen L. Suda,
585-387-9248maureen.suda@sagerx.com
Sage Therapeutics (NASDAQ:SAGE)
Historical Stock Chart
From Aug 2024 to Sep 2024
Sage Therapeutics (NASDAQ:SAGE)
Historical Stock Chart
From Sep 2023 to Sep 2024